From two doctors to 800,000 clinicians: Vera Health raises $28.5M

Vera Health has raised a $28.5 million Series A led by Threshold Ventures, with Optum Ventures, Mantis VC and SV Angel also in the round. Y Combinator and Gradient put in more money too, lifting the startup’s total funding to $32 million.

The company is trying to solve a very specific problem: doctors are drowning in medical research, and the pile gets bigger every day. Vera searches more than 60 million scientific publications, clinical guidelines and drug labels, then gives clinicians an answer with the supporting sources, the strength of the evidence and its limits spelled out. It is HIPAA- and GDPR-compliant and SOC 2 Type II certified, which matters because this is a tool that lives inside actual clinical workflows, not a demo video.

Growth has been fast. Vera says it started with two users, the founders’ physician fathers, and now reaches more than 800,000 clinicians in 190 countries. That includes roughly one in four physicians in Spain and Italy, and about one in seven in France. The company also says clinicians have gone from a few thousand questions a day to hundreds of thousands, and that only a few months after the Series A it had more daily active users than monthly active users at the time of the raise.

The product is built around trust, or the lack of it. Vera ranks evidence by study design, quality, cohort size, bias, recency and citation impact, and it was developed with clinicians who write medical guidelines. If studies or national rules conflict, it does not pretend the disagreement doesn’t exist. It shows the clash, the relative weight of the evidence and which guidance applies locally. For a doctor in France, that means French and European guidance first, French-language sources alongside the broader literature, and answers in French.

The company is also taking a hard line on monetisation. Vera is free for licensed clinicians and trainees, and the money comes from hospitals that want a more tailored, deeply integrated version. It does not run ads, and partners cannot buy a better placement for their content. The new funding will go into the evidence infrastructure, international expansion and more work with medical societies, publishers and health systems. Europe is a big part of that plan, and Vera’s bet is simple: in medicine, clear rules and clear sourcing are not a nuisance. They are the product.